Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer

J Thorac Oncol. 2019 Jan;14(1):e1-e3. doi: 10.1016/j.jtho.2018.06.020. Epub 2018 Jul 5.
No abstract available

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carbazoles / pharmacology
  • Carbazoles / therapeutic use*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Middle Aged
  • Organophosphorus Compounds / pharmacology
  • Organophosphorus Compounds / therapeutic use*
  • Piperidines / pharmacology
  • Piperidines / therapeutic use*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*

Substances

  • Carbazoles
  • Organophosphorus Compounds
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • brigatinib
  • alectinib